In a new study published in Nature Medicine, a team of Network researchers uncovered how tumours develop resistance to a specific type of immunotherapy targeted to a molecule called GPRC5D.
The overall vision of the PR2C is to create a collaborative, inclusive, equitable, and sustainable multiprovincial initiative that works towards developing new treatment strategies for patients facing...